RCUS (STOCKS)
Arcus Biosciences, Inc.
$22.390000
+0.050000 (+0.22%)
Prev close: $22.340000
Company Information
- Exchange
- XNYS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Terry J. Rosen
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,809.08M
- Employees
- 674
- P/E (TTM)
- -6.77
- P/B (TTM)
- 4.44
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $247.00M |
| Benefits Costs and Expenses | $600.00M |
| Costs And Expenses | $600.00M |
| Nonoperating Income/Loss | $33.00M |
| Operating Expenses | $633.00M |
| Depreciation and Amortization | $10.00M |
| Research and Development | $523.00M |
| Other Operating Expenses | $100.00M |
| Operating Income/Loss | -$386.00M |
| Income/Loss From Continuing Operations After Tax | -$353.00M |
| Income/Loss From Continuing Operations Before Tax | -$353.00M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$353.00M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$353.00M |
| Net Income/Loss Available To Common Stockholders, Basic | -$353.00M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Provision For Loan, Lease, And Other Losses | $0.00 |
| Basic Earnings Per Share | -$3.29 |
| Diluted Earnings Per Share | -$3.29 |
| Basic Average Shares | 107,400,000 |
| Diluted Average Shares | 107,400,000 |
| Assets | $1.14B |
| Current Assets | $1.01B |
| Noncurrent Assets | $132.00M |
| Fixed Assets | $40.00M |
| Other Non-current Assets | $92.00M |
| Liabilities | $508.00M |
| Current Liabilities | $231.00M |
| Accounts Payable | $42.00M |
| Wages | $33.00M |
| Other Current Liabilities | $156.00M |
| Noncurrent Liabilities | $277.00M |
| Long-term Debt | $99.00M |
| Other Non-current Liabilities | $178.00M |
| Equity | $631.00M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $631.00M |
| Liabilities And Equity | $1.14B |
| Net Cash Flow From Operating Activities | -$482.00M |
| Net Cash Flow From Operating Activities, Continuing | -$482.00M |
| Net Cash Flow From Investing Activities | $66.00M |
| Net Cash Flow From Investing Activities, Continuing | $66.00M |
| Net Cash Flow From Financing Activities | $488.00M |
| Net Cash Flow From Financing Activities, Continuing | $488.00M |
| Net Cash Flow | $72.00M |
| Net Cash Flow, Continuing | $72.00M |
| Comprehensive Income/Loss | -$353.00M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$353.00M |
| Other Comprehensive Income/Loss | $0.00 |
| Other Comprehensive Income/Loss Attributable To Parent | $0.00 |